CL2024001679A1 - Formas en estado sólido de un inhibidor de fgfr - Google Patents

Formas en estado sólido de un inhibidor de fgfr

Info

Publication number
CL2024001679A1
CL2024001679A1 CL2024001679A CL2024001679A CL2024001679A1 CL 2024001679 A1 CL2024001679 A1 CL 2024001679A1 CL 2024001679 A CL2024001679 A CL 2024001679A CL 2024001679 A CL2024001679 A CL 2024001679A CL 2024001679 A1 CL2024001679 A1 CL 2024001679A1
Authority
CL
Chile
Prior art keywords
solid state
state forms
fgfr inhibitor
forms
pyrrolidin
Prior art date
Application number
CL2024001679A
Other languages
English (en)
Spanish (es)
Inventor
W Kaldor Stephen
Tyhonas John
Kanouni Toufike
Kania Robert
M Cox Jason
P Reddy Jayachandra
Phimister Andrew
Chopade Shubham
Pandey Preetanshu
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of CL2024001679A1 publication Critical patent/CL2024001679A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
CL2024001679A 2021-12-08 2024-06-06 Formas en estado sólido de un inhibidor de fgfr CL2024001679A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163287212P 2021-12-08 2021-12-08

Publications (1)

Publication Number Publication Date
CL2024001679A1 true CL2024001679A1 (es) 2024-11-29

Family

ID=86731361

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001679A CL2024001679A1 (es) 2021-12-08 2024-06-06 Formas en estado sólido de un inhibidor de fgfr

Country Status (12)

Country Link
US (1) US20250059170A1 (https=)
EP (1) EP4444302A4 (https=)
JP (1) JP2024542840A (https=)
KR (1) KR20240119095A (https=)
CN (1) CN118804748A (https=)
AU (1) AU2022407440A1 (https=)
CA (1) CA3239792A1 (https=)
CL (1) CL2024001679A1 (https=)
IL (1) IL313359A (https=)
MX (1) MX2024006933A (https=)
TW (1) TW202332432A (https=)
WO (1) WO2023107980A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407439A1 (en) * 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10124003B2 (en) * 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
EP3969442A4 (en) * 2019-05-17 2023-08-02 Kinnate Biopharma Inc. FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS
US11345681B1 (en) * 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Also Published As

Publication number Publication date
TW202332432A (zh) 2023-08-16
IL313359A (en) 2024-08-01
KR20240119095A (ko) 2024-08-06
EP4444302A1 (en) 2024-10-16
WO2023107980A1 (en) 2023-06-15
AU2022407440A1 (en) 2024-06-20
CA3239792A1 (en) 2023-06-15
US20250059170A1 (en) 2025-02-20
CN118804748A (zh) 2024-10-18
EP4444302A4 (en) 2025-09-03
MX2024006933A (es) 2024-08-26
JP2024542840A (ja) 2024-11-15

Similar Documents

Publication Publication Date Title
CL2024001679A1 (es) Formas en estado sólido de un inhibidor de fgfr
EP4523755A3 (en) Quinazoline derivatives as antitumor agents
SA522441639B1 (ar) Egfr مثبطات تفارغية وطرق استخدامها
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
CO2022006712A2 (es) Inhibidores de las cinasas raf
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
DOP2019000250A (es) Composicion farmaceutica que comprende selexipag
MX2022001562A (es) Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
MX384206B (es) Formulaciones de inhibidores de dpp iv
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
CO2022018806A2 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
MX2024002391A (es) Inhibidores de indolina de kif18a.
EA201790950A1 (ru) Способы и композиции, в частности, для лечения синдрома дефицита внимания
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
CO2024009144A2 (es) Inhibidores de cinasa met
GEAP202215599A (en) Boron containing pde4 inhibitors
SA523440574B1 (ar) مثبطات إنترليوكين-17
PE20081308A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.